Psyence Biomedical Ltd.
PBM
$3.48
-$0.08-2.25%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 49.38% | 40.00% | 28.89% | 59.36% | 105.04% |
| Depreciation & Amortization | 20.93% | 59.38% | 138.10% | 327.27% | 2,050.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.54% | 51.12% | 30.32% | 68.54% | 75.46% |
| Operating Income | -69.54% | -51.12% | -30.32% | -68.54% | -75.46% |
| Income Before Tax | -1,946.88% | 78.47% | 92.28% | 94.21% | 99.35% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,946.88% | 78.47% | 92.28% | 94.21% | 99.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,946.88% | 78.47% | 92.28% | 94.21% | 99.35% |
| EBIT | -69.54% | -51.12% | -30.32% | -68.54% | -75.46% |
| EBITDA | -69.59% | -51.11% | -30.25% | -81.59% | -198.84% |
| EPS Basic | 57.95% | -68.61% | -- | -- | -- |
| Normalized Basic EPS | 33.03% | -115.03% | -- | -- | -- |
| EPS Diluted | 57.91% | -68.67% | -- | -- | -- |
| Normalized Diluted EPS | 33.03% | -115.03% | -- | -- | -- |
| Average Basic Shares Outstanding | 1,893.61% | 2,349.56% | -- | -- | -- |
| Average Diluted Shares Outstanding | 1,893.61% | 2,349.56% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |